Companies › Incannex Healthcare
1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IHL-42X Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an | CNR1, CNR2, CA2 | Phase 2 | Obstructive Sleep Apnea (OSA) | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07635563 | IHL-42X | Phase 2 | Obstructive Sleep Apnea (OSA) | Respiratory | Apr 2027 |
Cash of $68m on 2026-06-30; operating cash outflow about $13m a year; runway about 63 months at that burn, to Sep 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix
Contineum Therapeutics Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.